Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28213025 | 0.98 | KDM4E (0.57) | KDM4EALDH1A1TSHRNT5EPOLB | |
| SCHEMBL13825980 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1TSHRNT5EPOLB | |
| SCHEMBL20610117 | 0.77 | CA2 (0.44) | KDM4ETSHRPOLBTP53THRB | |
| SCHEMBL1156714 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1TSHRNT5EPOLB | |
| SCHEMBL6118994 | 0.75 | KDM4E (0.48) | KDM4EALDH1A1TSHRNT5EPOLB | |
| SCHEMBL2768266 | 0.75 | ALDH1A1 (0.44) | KDM4EALDH1A1POLBTP53THRB | |
| SCHEMBL1641672 | 0.75 | TP53 (0.42) | KDM4EPOLBTP53THRBLMNA | |
| SCHEMBL1700622 | 0.75 | KDM4E (1.00) | KDM4EALDH1A1TSHRNT5EHSD17B10 | |
| Hydrochloric Acid SCHEMBL27585913 | 0.73 | KDM4E (0.96) | KDM4EALDH1A1TSHRNT5EHSD17B10 | |
| SCHEMBL28293480 | 0.73 | ALDH1A1 (0.56) | KDM4EALDH1A1TSHRNT5EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | KDM4E 3838/4885ALDH1A1 3244/4885TSHR 4525/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | KDM4E 3838/4885ALDH1A1 3244/4885TSHR 4525/4885 |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | KDM4E 2161/4885ALDH1A1 2675/4885TSHR 2043/4885 |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | KDM4E 2240/4885ALDH1A1 2277/4885TSHR 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.